Your browser doesn't support javascript.
loading
Combined Fluorescence-Guided Surgery with 5-Aminolevulinic Acid and Fluorescein in Glioblastoma: Technical Description and Report of 100 Cases.
Pesaresi, Alessandro; La Cava, Pietro; Bonada, Marta; Zeppa, Pietro; Melcarne, Antonio; Cofano, Fabio; Fiaschi, Pietro; Garbossa, Diego; Bianconi, Andrea.
Afiliação
  • Pesaresi A; Neurosurgery Unit, Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.
  • La Cava P; Neurosurgery Unit, Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.
  • Bonada M; Neurosurgery Unit, Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.
  • Zeppa P; Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milan, Italy.
  • Melcarne A; Neurosurgery Unit, Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.
  • Cofano F; Neurosurgery Unit, Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.
  • Fiaschi P; Neurosurgery Unit, Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.
  • Garbossa D; Division of Neurosurgery, Ospedale Policlinico San Martino, IRCCS for Oncology and Neurosciences, Largo Rosanna Benzi 10, 16132 Genoa, Italy.
  • Bianconi A; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health, University of Genoa, Largo Rosanna Benzi 10, 16132 Genoa, Italy.
Cancers (Basel) ; 16(16)2024 Aug 06.
Article em En | MEDLINE | ID: mdl-39199544
ABSTRACT

BACKGROUND:

Fluorescence-guided resection (FGR) of glioblastomas has been previously explored with the use of 5-amivelulinic acid (5-ALA) and sodium fluoresceine (SF), allowing us to maximize the extent of resection (EoR). In this study, we highlight the most relevant concerns regarding this technique and present the methods and results from the experience of our center.

METHODS:

A case series of 100 patients operated on in AOU Città della Salute e della Scienza in Turin with a histological diagnosis of glioblastoma (grade IV, according to WHO 2021) was retrospectively analyzed. Both 5-ALA and SF were administered and intraoperatively assessed with an optical microscope.

RESULTS:

5-ALA is the only approved drug for FGR in glioblastoma, reporting an increased EoR. Nevertheless, SF can be positively used in addition to 5-ALA to reduce the risk of false positives without increasing the rate of adverse effects. In our experience, SF was used to guide the initial phase of resection while 5-ALA was used to visualize tumor spots within the surgical cavity. In 96% of cases, gross total resection was achieved, with supra-maximal resection in 11% of cases.

CONCLUSIONS:

Combined FGR using 5-ALA and SF seems to be a promising method of increasing the extent of resection and to improving the prognosis in glioblastoma patients.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2024 Tipo de documento: Article